Abstract
The treatment of brain diseases has been a major challenge since a long time. Although there are several potent drugs, which are highly therapeutic yet their efficiency is marred due to the presence of the Blood Brain Barrier (BBB). The BBB, which is present at the capillary level regulates and monitors the entry of all small and large molecules entering into the brain. Although this barrier is of immense importance to the brain in terms of safety, it becomes a hindrance when it comes to therapy because the drug molecules are unable to reach the brain. Various biomaterial-based strategies are being developed to overcome the BBB and deliver the drug into the brain. These include polymeric nanoparticles, liposomes, solid-lipid nanoparticles (SLNPs), nanogels, implants, etc. This review provides an overview on CNS disorders, BBB, and various delivery strategies available for biologists engaged in translational neuroscience, to target CNS.
Keywords: Blood-brain barrier (BBB), CNS drug delivery, drug transport, targeting.
Central Nervous System Agents in Medicinal Chemistry
Title:Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances
Volume: 14 Issue: 1
Author(s): Kritika Goyal, Veena Koul, Yashveer Singh and Akshay Anand
Affiliation:
Keywords: Blood-brain barrier (BBB), CNS drug delivery, drug transport, targeting.
Abstract: The treatment of brain diseases has been a major challenge since a long time. Although there are several potent drugs, which are highly therapeutic yet their efficiency is marred due to the presence of the Blood Brain Barrier (BBB). The BBB, which is present at the capillary level regulates and monitors the entry of all small and large molecules entering into the brain. Although this barrier is of immense importance to the brain in terms of safety, it becomes a hindrance when it comes to therapy because the drug molecules are unable to reach the brain. Various biomaterial-based strategies are being developed to overcome the BBB and deliver the drug into the brain. These include polymeric nanoparticles, liposomes, solid-lipid nanoparticles (SLNPs), nanogels, implants, etc. This review provides an overview on CNS disorders, BBB, and various delivery strategies available for biologists engaged in translational neuroscience, to target CNS.
Export Options
About this article
Cite this article as:
Goyal Kritika, Koul Veena, Singh Yashveer and Anand Akshay, Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances, Central Nervous System Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/1871524914666141030145948
DOI https://dx.doi.org/10.2174/1871524914666141030145948 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Insight into Molecular Mechanisms and Novel Therapeutic Approaches in Epileptogenesis
CNS & Neurological Disorders - Drug Targets Volumetric Changes in the Basal Ganglia After Antipsychotic Monotherapy: A Systematic Review
Current Medicinal Chemistry Advanced Methods for the Analysis of Testosterone
Current Medicinal Chemistry Fast-Dissolving Solid Dispersions for the Controlled Release of Poorly Watersoluble Drugs
Current Pharmaceutical Design Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Pediatric Differentiated Thyroid Cancer: When to Perform Conservative and Radical Surgery
Current Pediatric Reviews [177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma
Current Radiopharmaceuticals Nuclear Imaging of Inflammation in Neurologic and Psychiatric Disorders
Current Clinical Pharmacology Morbidity and Mortality Associated with Pharmacotherapy. Evolution and Current Concept of Drug-Related Problems
Current Pharmaceutical Design Macrophage Activation Syndrome in Childhood Rheumatic Diseases
Current Rheumatology Reviews tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mice with Liver Composed of Human Hepatocytes as an Animal Model for Drug Testing
Current Drug Discovery Technologies Recent Evidence of the Regulatory Role of PPARs in Neural Stem Cells and Their Underlying Mechanisms for Neuroprotective Effects
Current Stem Cell Research & Therapy Effective Preparation, Characterization and In Situ Surface Coating of Superparamagnetic Fe3O4 Nanoparticles with Polyethyleneimine Through Cathodic Electrochemical Deposition (CED)
Current Nanoscience Oncogenic Signaling in Acute Myeloid Leukemia
Current Drug Targets Role of Apoptosis in the Pathogenesis of Common Variable Immunodeficiency (CVID)
Endocrine, Metabolic & Immune Disorders - Drug Targets Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery New Frontiers in Cystic Fibrosis Therapy: The Case of Stem Cells
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) A Review on Post-traumatic Stress Disorder (PTSD): Symptoms, Therapies and Recent Case Studies
Current Molecular Pharmacology ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology
Current Medicinal Chemistry